Executive Summary: This IP-NFT covers a novel electrochemical platform designed to control protein tertiary structure during biomanufacturing. By applying precise electrostatic fields (10-1000 V/m), the system guides protein folding pathways toward native conformations, significantly increasing the yield of complex therapeutic proteins, including GPCRs and monoclonal antibodies. The Problem: Misfolding is a multi-billion dollar bottleneck in the pharmaceutical industry. Traditional folding methods rely on passive chemical environments, often resulting in low yields of active protein, aggregation, and high purification costs. Many promising therapeutic targets remain "undruggable" due to these manufacturing limitations. The Solution: Our platform introduces active control over the folding environment. Using tunable electrode geometries and real-time monitoring (Circular Dichroism and Impedance Spectroscopy), the system provides a template-like electrostatic effect. This ensures that proteins reach their biologically active state with 85-95% native yield, representing a 3-6 fold improvement over traditional industrial benchmarks. Key Technical Advantages: High Yield: Drastic reduction in aggregation-prone intermediates. Versatility: Applicable to diverse targets: ion channels, toxic antigens, and complex antibodies. Real-Time Analytics: Integrated sensors for continuous monitoring of protein conformation during the process. Scalability: Modular reactor design compatible with existing bioreactor lines (from 1L to 10,000L). IP & Commercial Value: The technology is backed by a comprehensive patent application covering hardware configuration, waveform parameters, and integration methods. It is currently at TRL 4 (validated in a lab environment). This asset is ideal for Bio-CDMOs and pharmaceutical companies seeking to unlock difficult-to-express protein pipelines. Affiliation: Teplov Electrochemical Research | Caltech Alumni Network Contact: Teplov.a.g@gmail.com